Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham Jackson

Showing results (201-210 of 251) with videos related to

Pageof 26
Sort By:
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.
British Journal of Haematology|June 12, 2020
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myelomaCeri Bygrave, Charlotte Pawlyn, Faith Davies, et al.
Leukemia Research|February 15, 2011
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myelomaLuis R de Brito, Mike A Batey, Yan Zhao, et al.
Blood|November 16, 2011
A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemiaNicola J Sunter, Kathryn Scott, Robert Hills, et al.
BMC Cancer|August 8, 2025
Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial dataMartin Kortüm, Sebastian Theurich, James Farrell, et al.
Forensic Science International|June 3, 2018
A response to "Likelihood ratio as weight of evidence: A closer look" by Lund and IyerSimone Gittelson, Charles E H Berger, Graham Jackson, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI TrialSarah Bird, David Cairns, Tom Menzies, et al.
Forensic Science International|March 24, 2020
A review of likelihood ratios in forensic science based on a critique of Stiffelman "No longer the Gold standard: Probabilistic genotyping is changing the nature of DNA evidence in criminal trials"John Buckleton, Bernard Robertson, James Curran, et al.
British Journal of Haematology|June 3, 2017
Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain testsJennifer L J Heaney, John P Campbell, Anne E Griffin, et al.
Leukemia|June 22, 2018
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trialsJennifer L J Heaney, John P Campbell, Gulnaz Iqbal, et al.
Pageof 26

Showing results (201-210 of 251) with videos related to

Sort By:
Pageof 26
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.
British Journal of Haematology|June 12, 2020
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myelomaCeri Bygrave, Charlotte Pawlyn, Faith Davies, et al.
Leukemia Research|February 15, 2011
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myelomaLuis R de Brito, Mike A Batey, Yan Zhao, et al.
Blood|November 16, 2011
A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemiaNicola J Sunter, Kathryn Scott, Robert Hills, et al.
BMC Cancer|August 8, 2025
Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial dataMartin Kortüm, Sebastian Theurich, James Farrell, et al.
Forensic Science International|June 3, 2018
A response to "Likelihood ratio as weight of evidence: A closer look" by Lund and IyerSimone Gittelson, Charles E H Berger, Graham Jackson, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI TrialSarah Bird, David Cairns, Tom Menzies, et al.
Forensic Science International|March 24, 2020
A review of likelihood ratios in forensic science based on a critique of Stiffelman "No longer the Gold standard: Probabilistic genotyping is changing the nature of DNA evidence in criminal trials"John Buckleton, Bernard Robertson, James Curran, et al.
British Journal of Haematology|June 3, 2017
Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain testsJennifer L J Heaney, John P Campbell, Anne E Griffin, et al.
Leukemia|June 22, 2018
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trialsJennifer L J Heaney, John P Campbell, Gulnaz Iqbal, et al.
Pageof 26